Zobrazeno 1 - 10
of 62
pro vyhledávání: '"Rosane, Charlab"'
Autor:
Rosane Charlab, Rebecca Racz
Publikováno v:
Clinical and Translational Science, Vol 16, Iss 8, Pp 1331-1339 (2023)
Abstract NUT midline carcinoma family member 1 (NUTM1) fusions were originally identified in poorly differentiated and clinically aggressive carcinomas typically located in the midline structures of children and young adults, and collectively known a
Externí odkaz:
https://doaj.org/article/a6367ca3b2bb486d89e22f1207ae6646
Autor:
Jaleh Fallah, Michael H. Brave, Chana Weinstock, Gautam U. Mehta, Diana Bradford, Haley Gittleman, Erik W. Bloomquist, Rosane Charlab, Salaheldin S. Hamed, Claudia P. Miller, Sarah E. Dorff, Wiley A. Chambers, Bronwyn D. Mixter, Jeannette Dinin, William F. Pierce, Tiffany K. Ricks, Shenghui Tang, Martha Donoghue, Richard Pazdur, Laleh Amiri-Kordestani, Amna Ibrahim, Julia A. Beaver
Publikováno v:
Clin Cancer Res
On August 13, 2021, the FDA approved belzutifan (WELIREG, Merck), a first-in-class hypoxia-inducible factor (HIF) inhibitor for adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d366bff8662137a824aa2634279d526
https://doi.org/10.1158/1078-0432.ccr-22-1054
https://doi.org/10.1158/1078-0432.ccr-22-1054
Autor:
Lola A. Fashoyin-Aje, Marc R. Theoret, Steven J. Lemery, Richard Pazdur, Shenghui Tang, Matthew D. Thompson, Hong Zhao, Elizabeth I. Spehalski, Rosane Charlab, Sirisha L. Mushti, Margaret Thompson, Leslie Doros, Vaibhav Kumar
FDA Benefit Risk Assessment and Summary
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4e9e89b32ad021953ce08834133b2280
https://doi.org/10.1158/1078-0432.22489056
https://doi.org/10.1158/1078-0432.22489056
Autor:
Richard Pazdur, Ann T. Farrell, Kirsten B. Goldberg, Gene M. Williams, Rosane Charlab, Christopher M. Sheth, Yuan-Li Shen, Albert Deisseroth, Donna Przepiorka, Sarah E. Dorff, Ramadevi Gudi, Vicky Hsu, Lola Luo, Kelly J. Norsworthy
Rate of CR+CRh by subgroup
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2be902c39ee395a68d595086357bb634
https://doi.org/10.1158/1078-0432.22469381.v1
https://doi.org/10.1158/1078-0432.22469381.v1
Autor:
Harpreet Singh, Marc R. Theoret, Richard Pazdur, Julia A. Beaver, Paul G. Kluetz, Shenghui Tang, Autumn Zack-Taylor, Reena Philip, Donna Roscoe, Soma Ghosh, Dun Liang, Francisca Reyes Turcu, Rosane Charlab, Jiang Liu, Yangbing Li, Jeanne Fourie Zirkelbach, Lauren S.L. Price, Whitney S. Helms, Amy M. Skinner, Lisa Rodriguez, Sirisha L. Mushti, Erin Larkins, Diana Bradford
On May 8, 2020, the FDA granted accelerated approval to selpercatinib for (i) adult patients with metastatic RET fusion–positive non–small cell lung cancer (NSCLC), (ii) adult and pediatric patients ≥12 years of age with advanced or metastatic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be7343eb8f94d802c06ee615ed48b00e
https://doi.org/10.1158/1078-0432.c.6531198.v1
https://doi.org/10.1158/1078-0432.c.6531198.v1
Autor:
Richard Pazdur, Ann T. Farrell, Kirsten B. Goldberg, Gene M. Williams, Rosane Charlab, Christopher M. Sheth, Yuan-Li Shen, Albert Deisseroth, Donna Przepiorka, Sarah E. Dorff, Ramadevi Gudi, Vicky Hsu, Lola Luo, Kelly J. Norsworthy
Preferred Terms included in grouped terms
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::477f921b3577155839505aca83b12450
https://doi.org/10.1158/1078-0432.22469378
https://doi.org/10.1158/1078-0432.22469378
Autor:
Harpreet Singh, Julia A. Beaver, Marc R. Theoret, Richard Pazdur, Reena Philip, Soma Ghosh, Dun Liang, Hong Zhao, Jiang Liu, Rosane Charlab, Jielin Sun, Youwei Bi, Amal Ayyoub, Whitney S. Helms, Emily Wearne, Pallavi S. Mishra-Kalyani, Somak Chatterjee, Lee H. Pai-Scherf, Erin Larkins, Diana Bradford, Janice Kim
Supplementary Tables S1-S3
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e4b5d26de3d7ddf0a7029f07d3d7773
https://doi.org/10.1158/1078-0432.22481316.v1
https://doi.org/10.1158/1078-0432.22481316.v1
Autor:
Richard Pazdur, Ann T. Farrell, Kirsten B. Goldberg, Gene M. Williams, Rosane Charlab, Christopher M. Sheth, Yuan-Li Shen, Albert Deisseroth, Donna Przepiorka, Sarah E. Dorff, Ramadevi Gudi, Vicky Hsu, Lola Luo, Kelly J. Norsworthy
The FDA approved ivosidenib (Tibsovo; Agios), a small-molecule inhibitor of isocitrate dehydrogenase (IDH)1 on July 20, 2018, for treatment of adults with relapsed or refractory acute myeloid leukemia (R/R AML) with susceptible IDH1 mutation as detec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::73f76bad34dda06affe9b958f7b8772b
https://doi.org/10.1158/1078-0432.c.6527243
https://doi.org/10.1158/1078-0432.c.6527243
Autor:
Richard Pazdur, R. Angelo de Claro, Ann T. Farrell, Julia A. Beaver, Rajeshwari Sridhara, Dickran Kazandjian, Albert Deisseroth, Sarah E. Dorff, Rosane Charlab, Donna Przepiorka, Ashley F. Ward, Emma C. Scott, Flora Mulkey, Kelly J. Norsworthy
Supplementary Figure 1. Detailed flow diagram for ascertainment of DS cases.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92fb0954902c2407558ec6d5284e8399
https://doi.org/10.1158/1078-0432.22476204.v1
https://doi.org/10.1158/1078-0432.22476204.v1
Autor:
Richard Pazdur, R. Angelo de Claro, Ann T. Farrell, Julia A. Beaver, Rajeshwari Sridhara, Dickran Kazandjian, Albert Deisseroth, Sarah E. Dorff, Rosane Charlab, Donna Przepiorka, Ashley F. Ward, Emma C. Scott, Flora Mulkey, Kelly J. Norsworthy
Supplementary Figure 2. Relative risk of DS for frequently co-mutated genes.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::71d8d24c05387f09c3b40e96cbe4a207
https://doi.org/10.1158/1078-0432.22476201
https://doi.org/10.1158/1078-0432.22476201